after joining the study, a complete medical history is recorded and baseline laboratory tests, electrocardiogram (ecg) and vital‑sign measurements are performed.

the tumor type (colorectal cancer) is confirmed and imaging studies are obtained to define the initial disease status.

the investigational drug gsk5460025a is taken orally in capsule form.

the exact dose, frequency and length of treatment are defined by the study protocol and are not specified in the provided information.

during the initial observation period, which is used to identify any dose limiting toxicities (dlt), the participant is monitored closely for serious or severe adverse reactions.

laboratory values, ecg results and vital signs are checked regularly throughout this period.

if adverse events occur, the study team records each event by severity and may adjust the dose of gsk5460025a according to predefined criteria.

all treatment‑emergent adverse events (teae) and treatment‑emergent serious adverse events (tesae) are documented.

treatment continues as long as the disease does not progress and toxicity remains acceptable.

periodic imaging is performed to evaluate tumor response using the recist 1.1 criteria, which classify responses as complete response (cr), partial response (pr), stable disease or progressive disease.

the primary efficacy measure in part 2 is the objective response rate (orr), defined as the proportion of participants with a confirmed cr or pr.

treatment is stopped when disease progression is documented, when unacceptable toxicity occurs, or at the discretion of the investigator.

final safety and efficacy data are collected, including plasma concentrations of gsk5460025a and any lasting changes in laboratory parameters, ecg, or vital signs.